Synaptogenix, Inc. (NASDAQ: SNPX) has recently made headlines with its significant achievement in the field of neurodegenerative disease treatment. The pioneering biopharmaceutical company has received a Notice of Allowance for its U.S. Patent Application 17/665,033 titled "Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Ne...
$Synaptogenix(SNPX.US)$Synaptogenix Has Received A Notice Of Allowance For Its U.S. Patent Application 17/665,033 Titled "Halogenated Esters Of Cyclopropanated Unsaturated Fatty Acids For Use In The Treatment Of Neurodegenerative Diseases"
$Synaptogenix(SNPX.US)$Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
71633929 : 這什麼時候會再次彈出
Stock_Drift樓主 71633929: $Jaguar Health (JAGX.US)$ ?